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Background:  It is well-established that many risk factors for breast cancer are related to 
estrogen or reproductive factors.  Two estrogen metabolites of particular interest are 2-
hydroxyestrone (2-OHE) and 16α-hydroxyestrone (16α-OHE) which are often reported 
together as a ratio of 2:16α-hydroxyestrone (2:16α –OHE).  It has been demonstrated in 
several studies that postmenopausal women who are at a higher risk of breast cancer tend 
to have increased levels of 16α-OHE or decreased levels of 2-OHE levels in the body.  
Recent studies have shown that the phytochemical indole-3-carbinol (I3C), found in 
Brassica vegetables, impacts the conversion of 2-OHE, known as “good estrogen”, by 
inducing the enzyme CYP1A1; however, research on the effects of Brassica vegetable 
consumption on the 2:16α-OHE ratio in randomized clinical settings is still sparse.  The 
objective of this study is to examine whether an increase in Brassica vegetable 
consumption would alter the 2:16α-OHE estrogen metabolite ratio among 
postmenopausal women, by increasing 2-OHE and decreasing 16α-OHE.   
Methods:  Postmenopausal African American and European American women who 
resided in the standard metropolitan statistical area (SMSA) around the Columbia, South 
Carolina area were recruited between April 2002 and September 2003 for a nine-week 
dietary intervention.  The women were randomized into one of two arms, intervention 
group or non-intervention (control group), during the first clinic.  The women 
randomized to the intervention group were offered nine classes that were led by trained 
study dietitians over a three-week dietary intervention geared at increasing the
vii 
consumption of Brassica vegetables daily at home; whereas, those in the control group 
were asked to maintain their usual dietary habits for the duration of the study period. The 
study population that was used for analysis consisted of 64 women who attended both 
clinic visits with complete urine, dietary data, and baseline information. 
Results: Compared to baseline levels, Brassica vegetable intake significantly increased 
in the intervention group by 6-fold when compared to the control group during the 
intervention; whereas, post intervention, Brassica intake only increased in the 
intervention about 3.5-fold when compared to the control group.  At post intervention, 
there were no statistically significant differences between the intervention and control 
groups in 2-OHE (10.6 ng/ml vs. 8.7 ng/ml, respectively, p=0.4), 16α-OHE (9.6 ng/ml vs. 
8.6 ng/ml, respectively, p=0.6) and 2:16α-OHE (1.3 ng/ml vs. 1.3 ng/ml, respectively, 
p=0.7) levels.  The effect of the intervention was determined separately for high and low 
Brassica vegetable consumers at baseline, stratified by race, and stratified by breast 
cancer survivorship status but these did not appear to modify the effect of the intervention 
on 2-OHE, 16α-OHE, or 2:16α-OHE levels after adjustment for covariates. 
Conslusion: These findings suggest that Brassica vegetables do not play a role in the 
modification of 2-OHE and 2:16α-OHE metabolite levels among postmenopausal women 
in a short, three-week intervention.  These findings highlight the need for future research 
to further understand the biological mechanism between estrogen metabolites and 
Brassica vegetable consumption. Future research is needed to determine whether a larger 
increase in Brassica vegetables could affect estrogen metabolites and to examine whether 
genes may modify the effect of Brassica vegetables on estrogen metabolites.
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Statement of the Problem 
With the exclusion of skin cancer, breast cancer is the most commonly diagnosed 
cancer among women in the United States, accounting for approximately 1 in 3 cancers 
(DeSantis et al. 2013). The lifetime risk for a woman born today to develop breast cancer 
is 1 in 8 women (SEER, Stat Fact Sheets: Breast Cancer 2006-2010).    In 2013, it is 
estimated that 232, 340 women will be diagnosed with invasive breast cancer (SEER, 
Stat Fact Sheets: Breast Cancer 2006-2010). In 2012, it was estimated that approximately 
2.9 million women alive in the United States had a history of breast cancer (American 
Cancer Society, Breast Cancer Facts & Figures 2013-2014).  Beginning in the 1980‟s, 
there was a sharp increase in breast cancer incidence rates which was likely due to the 
greater use of mammography screening leading to increased early detection of cases 
(American Cancer Society, Breast Cancer Facts & Figures 2013-2014).  Between 2002 
and 2003, rates drastically decreased; furthermore, since then, the rate of breast cancer 
incidence has remained relatively stable (American Cancer Society, Breast Cancer Facts 
& Figures 2013-2014).  In 2013, it is estimated that 39,620 women will die of invasive 
breast cancer (DeSantis et al. 2013; SEER, Stat Fact Sheets: Breast Cancer 2006-2010).  
Some of the known risk factors for breast cancer include age, family history of breast 
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cancer, early age at first menarche, late age at menopause, nulliparity, late age at first 
birth, and hormone replacement therapy (American Cancer Society, Breast Cancer Facts 
& Figures 2013-2014).  The five-year relative survival rate of breast cancer is highly 
correlated with stage of disease at diagnosis; meaning that as stage increases, survival 
rate decreases (American Cancer Society, Breast Cancer Facts & Figures 2013-2014).  
The breast cancer five-year relative survival rate has been increasing since 1975 in both 
European American (EA) and African American (AA) women; however, there seems to 
be a widening health disparity gap that exists between EA and AA women on breast 
cancer mortality (American Cancer Society, Breast Cancer Facts & Figures 2013-2014). 
 AA women are less likely to be diagnosed with breast cancer than their EA 
counterparts; however, AA women are more likely to die of breast cancer than EA when 
they are diagnosed (DeSantis et al. 2013; SEER, Stat Fact Sheets: Breast Cancer 2006-
2010; Adams et al. 2006; Menashe et al. 2009). Furthermore, AA‟s are burdened with 
more aggressive forms of breast cancer (DeSantis et al. 2013; SEER, Stat Fact Sheets: 
Breast Cancer 2006-2010; Adams et al. 2006; Menashe et al. 2009).  
 
According to the 
SEER data from 2006-2010, the incidence rate for EA and AA women were 127.4 and 
121.4 cases per 100,000 women, respectively.  The age-adjusted mortality rate for EA 
and AA women respectively were 22.1 and 30.8 deaths per 100,000 women; moreover, 
the overall 5-year relative survival rate 2006-2010 was 92% for EA and only 79% for AA 
women (SEER, Stat Fact Sheets: Breast Cancer 2006-2010; American Cancer Society, 
Breast Cancer Facts & Figures 2013-2014).  Therefore, not only is it important to focus 
on breast cancer reduction among all women in general in the United States, but to also 
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determine why AA women tend to present with more advanced stages of the disease and 
are more likely to die from breast cancer compared to other racial/ethnic groups. 
Both environmental and biological factors affect the risk of breast cancer (Maizes 
2005).  Similar to other cancers, breast cancer risk has been linked to poverty, limited 
access to health care, lower education, and lower income (Leepeak et al. 2011; Tian et al. 
2011; Merkin et al. 2002; Tian et al. 2010; Komenaka et al. 2010; Simon et al. 2006).  
Diet has also become a recognizable environmental risk factor associated with the risk of 
a number of cancers, including breast cancer (Ramirez et al. 2009; Higdon et al. 2007; 
Kim et al. 2009; World Cancer Research Fund/American Institute for Cancer Research 
2007).  The link between vegetables in general and the risk of breast cancer has been 
well-established over the last decade through numerous studies (Willet 2001; La Vecchia 
et al. 2001; Riboli et al. 2003; Gandini et al. 2001; Cottet et al. 2009).  The combined 
study analysis of the Italian breast cancer studies by La Vecchia et al. (2001) and a meta-
analysis by Gandini et al. (2001) of 23 studies concluded that increased vegetable 
consumption reduced breast cancer risk by 20 to 25%.   Furthermore, Cottet et al. (2009) 
utilized the EPIC cohort to investigate the association between dietary pattern and risk of 
postmenopausal invasive breast cancer (n=2, 381).  This study compared the 
Mediterranean diet of the Italians (consists mostly of fruits, raw vegetables, cooked 
vegetables, crustaceans, fish, olive oil and sunflower oil) to a more westernized diet 
(consists of alcohol, meat and processed foods).  Two dietary patterns were observed to 
be associated with postmenopausal breast cancer risk: (1) higher risk of breast cancer was 
associated with western-type foods and alcohol; and (2) reduced risk of breast cancer was 
associated with Mediterranean pattern diets that were high in fruits, vegetables, fish, and 
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olive and sunflower oils (Cottet et al. 2009).  Overall, this study suggests that the risk of 
postmenopausal breast cancer in women may be impacted by dietary habits, particularly 
following a Mediterranean-type diet may reduce risk (Cottet et al. 2009).  These studies 
have helped garner interest on the role of specific types of vegetables that may be even 
more influential on breast cancer than just vegetables as a whole, particularly Brassica 
vegetables. 
Brassica vegetables, like broccoli, cabbage, Brussels sprouts, cauliflower, kale, 
turnips and collards, contain a number of nutrients and phytochemicals that have cancer 
chemopreventive properties such as glucosinolates (which are converted to 
isothiocyanates and indoles), folate, fiber, carotenoids, vitamin C and chlorophyll 
(Higdon et al. 2007; Kim et al. 2009).  An extensive review of epidemiologic studies 
published prior to 1996 by Higdon et al. (2007) reported that 67% of a total of 87 case-
control studies found an inverse association between cancer risk and some type of 
Brassica vegetable; in particular, results were consistent among lung and stomach cancer. 
For breast cancer, the Higdon et al. paper reported that three studies found inverse 
associations between Brassica vegetables and breast cancer, while a pooled analysis of 
seven large prospective cohort studies found no association. Therefore, researching the 
link between Brassica vegetables and breast cancer risk is critical (Kim et al. 2009).   
It is well-established that many risk factors for breast cancer are related to 
estrogen or reproductive factors.  Two estrogen metabolites of particular interest are 2-
 
hydroxyestrone (2-OHE) and 16α-hydroxyestrone (16α-OHE) which are often reported 
together as a ratio of 2:16α-hydroxyestrone ratio (2:16α-OHE) (Bradlow et al. 1994; Lord 
et al. 2002; Nguyen et al. 2010; Laidlaw et al. 2010).  A higher incidence of disease is 
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associated with high levels of 16α-OHE and low levels of 2-OHE in the body in some 
studies (Matthews et al. 2004; Musey et al. 1987), but not all (Obi et al. 2011; Lissowska 
et al. 2008; Ursin et al. 1999; Cauley et al. 2003; Wellejus et al. 2005).  The 16α-OHE 
estrogen metabolite has high estrogenic activity, which has been found to enhance cell 
proliferation in estrogen sensitive breast cancers; whereas 2-OHE has antiestrogenic 
properties (Obi et al. 2011; Higdon et al. 2009; Lord et al. 2002).   It has been 
demonstrated in several studies that postmenopausal women who are at a higher risk of 
breast cancer tend to have significantly increased levels of 16α-OHE or decreased levels 
of 2-OHE levels in the body (Kabat et al. 1997; Lord et al. 2002; Coker et al. 1997; Ho et 
al. 1998). The hydroxylation of one of these metabolites has been suggested to lower the 
concentration of the other one because the precursor is the same between them (Bradlow 
et al. 1996; Falk et al. 2000).  In general, studies have shown that the estrogen 
metabolism pathways that favor 2-OHE over 16α-OHE are associated with reduced risk 
of invasive breast cancer (Coker et al. 1997; Muti et al. 2000; Taioli et al. 1996; Sowers 
et al. 2006; Im et al. 2009; Kabat et al. 2006; Fowke et al. 2003; Meilahn et al. 1998). 
The enzyme CYP1A1 catalyzes the conversion of estrone to 2-OHE; while the 
conversion of estrone to 16α-OHE is triggered by the enzyme CYP1B1 (Lord et al. 2002) 
(Figure 1.1).  Studies have shown that the phytochemical indole-3-carbinol (I3C), found 
in Brassica vegetables (e.g., cabbage, broccoli, kale, turnips, collards, cauliflower, and 
Brussels sprouts), impacts the conversion of 2-OHE, known as “good estrogen”, by 
inducing CYP1A1 (Lord et al. 2002; Nguyen et al. 2010; Laidlaw et al. 2010).  The major 
in vivo product of I3C is 3, 3‟ diindolylmethane (DIM; 1,2); it is thought that DIM is the 
major mediator of chemopreventive and chemotherapeutic effects of I3C (Dalessandri et 
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al. 2004).  Both I3C and DIM can induce the enzyme which converts estrone to 2-OHE at 
the expense of 16α-OHE (Dalessandri et al. 2004).   A few studies have significantly 
shown an increase in 2-OHE urinary metabolite levels after consumption of I3C (Nguyen 
et al. 2010; Laidlaw el al. 2010; Marconett et al. 2010).  Other studies have demonstrated 
that I3C is an inhibitor of human breast cancer cell proliferation (Nguyen et al. 2010; 






         Figure 1.1 Estrone Metabolism Pathway 
  Research on the effects of Brassica vegetable consumption on the 2:16α-OHE 
ratio in randomized clinical settings is still sparse.  Kall et al. (1997) found that the 
average 2:16α-OHE ratio significantly increased by 29.5% (p<0.05) after a group of 18 
volunteers increased their consumption of broccoli to 500g/day for 12 days.  Though this 
was a very short experimental study with no control group, the results support the idea 
that Brassica vegetables may potentially increase the 2:16α-OHE ratio.  Furthermore, a 
randomized controlled trial by Fowke et al. (2000) found that a 20-fold increase in grams 
of Brassica vegetables consumed among 34 healthy postmenopausal women significantly 
increased their urinary 2:16α-OHE ratios.
   
 However, the effects of Brassica vegetables 
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on the 2:16α-OHE ratio among AA women and breast cancer survivors has not been 
thoroughly examined.  
Proposal and Specific Aims 
 Using a previously-conducted randomized controlled trial in South Carolina, I 
hypothesized that an increase in Brassica vegetable consumption would alter the 2:16α-
OHE estrogen metabolite ratio among postmenopausal women, by increasing 2-
hydroxyestrone (2-OHE) and decreasing 16α-hydroxyestrone (16α-OHE). 
 The specific aims are as follows: 
Aim 1: To evaluate the effect of the Brassica intervention on the 2:16α-OHE 
ratio, specifically to examine whether women in the Brassica intervention 
arm experienced an increase in 2-OHE or in the ratio of 2:16α-OHE 
compared to the women in the control (non-intervention) arm. 
Aim 2: To evaluate the effect of the intervention on the 2:16α-OHE ratio by 
baseline dietary intake, examining whether diet before the Brassica 
intervention began impacted the results of the intervention.  
 Aim 3: To evaluate if the effect of the intervention on 2:16α-OHE ratio differs by 
race or breast cancer status, by comparing the mean effect of the 
intervention among EA and AA women and among breast cancer cases 
and healthy women enrolled in the study. 
Significance and Research 
 Approximately one-third of all cancer cases are related to dietary influences (Lord 
et al. 2002).  Numerous studies have shown that breast cancer risk increases with 
increasing exposure to estrogen in the body, especially by increased levels of 16α-OHE 
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in the presence of low levels of 2-OHE (Lord et al. 2002; Coker et al. 1997; Muti et al. 
2000; Taioli et al. 1996; Sowers et al. 2006).  Furthermore, the 2:16α-OHE is perhaps 
modifiable by diet and lifestyle interventions (Lord et al. 2002).  There is growing 
evidence that favors the modification of the 2:16α-OHE ratio by increasing Brassica 
vegetable consumption.  It is vital for epidemiologist to further understand this biological 
mechanism between estrogen metabolites and Brassica vegetable consumption because it 
could lead to a possible preventive measure to reduce the risk of breast cancer among 
women as well as the risk of other comorbidities.   
 It is also important to address the health disparity that exists between EA and AA 
women in terms of breast cancer mortality.  It has been observed that AA women tend to 
have lower 2:16α-OHE estrogen metabolite ratio levels than EA women (Sowers et al. 
2006; Lord et al. 2002; Matthews et al. 2004; Musey et al. 1987).  This is likely due to 
both SES and biological factors; however, if Brassica interventions can potentially be a 
way to reduce breast cancer among all races, then breast cancer mortality will drop 
among AA women as well. 
  The present study utilized data from a previously-conducted randomized 
controlled trial in South Carolina among postmenopausal women.   Brassica vegetables 
have been linked to lowering the risk of other types of cancers, like lung and colorectal 
cancer in some epidemiological studies; therefore, the research on this topic of Brassica 
vegetables and breast cancer risk is critical (Kim et al. 2009).  The 2:16α-OHE ratio can 
be potentially modified through lifestyle factors like diet.  A study such as this could help 
in understanding the biological mechanism of the link between Brassica vegetables and 
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breast cancer risk.  Subsequently, this may help to inform future interventions designed to 






PART I:  Brassica Vegetables and Breast Cancer  
 It has been estimated that one-third of all cancer cases are related to dietary 
influence (Lord et al. 2002).  Over the last several decades a number of epidemiological 
studies have observed an inverse association between Brassica vegetable consumption 
and cancer, in particular breast cancer (Lord et al. 2002; Kim et al. 2009).  Brassica 
vegetables are rich sources of glucosinolates (precursors to isothiocyanates and I3C), 
carotenoids, vitamin C, folate and soluble fiber, which may potentially play an important 
factor in cancer prevention (Kim et al. 2009); however, epidemiologic studies on 
Brassica vegetable consumption and breast cancer are inconsistent.  Case-control studies 
have reported significant inverse associations between the risk of breast cancer and 
Brassica vegetable consumption over the last decade or so (Ambrosone et al. 2004; Terry 
et al. 2001; Fowke et al. 2003; Riboli et al. 2003; Gaudet et al. 2004); whereas, 
prospective cohorts have yielded inconsistent results with the association being weak or 
non-existent (Boggs et al. 2010; Masala et al. 2012; Cottet et al. 2009; Smith-Warner et 
al. 2001; Van Gils et al. 2005; Agurs-Collins et al. 2009).   
In the Long Island Breast Cancer Study Project case-control study (1,463 cases 
and 1,500 controls), breast cancer risk decreased by more than one-third in the highest 
quintile of any vegetables [OR, 0.63; 95%CI, 0.48-0.86] or leafy vegetables [OR, 0.66; 
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95%CI, 0.50-0.85] intake when compared with women in the lowest quintile; 
furthermore, a 34% reduced risk was observed with an intake of nine or more 0.5 cup 
servings/week of leafy vegetables among postmenopausal women (Gaudet et al. 2004).  
They also found a weaker inverse association between Brassica vegetables and breast 
cancer risk in postmenopausal women [OR, 0.80; 95%CI, 0.60-1.05] (Gaudet et al. 
2004).   
Three other case-control studies by Ambrosone et al. (2004), Fowke et al. (2003), 
and Terry et al. (2001) also found an inverse association between Brassica vegetable 
intake and breast cancer risk.  The Ambrosone et al. (2004) paper reported results from 
the Western New York Diet Study which was conducted among EA pre and 
postmenopausal women.  They found a marginal inverse association between Brassica 
vegetable consumption, especially broccoli, and breast cancer risk among premenopausal 
women but only a weak or obsolete association among postmenopausal women 
(Ambrosone et al. 2004).  Fowke et al. (2003) further demonstrated this among Chinese 
women in Shanghai, China by observing that greater Brassica vegetable consumption, 
measured by the urinary ITC biomarker, was associated with significantly reduced breast 
cancer risk.  In postmenopausal Chinese women, there was a marginally significant 
protective trend attributed to the highest quintile of self-reported Brassica consumption 
and breast cancer (Crude OR, 0.40; 95% CI, 0.2-1.0) (Fowke et al. 2003).  The Swedish 
Study by Terry et al. (2001) was only conducted among postmenopausal women and 
found that the upper decile (10%) of Brassica vegetable consumption was associated with 
a 40% lower risk of breast cancer.  The relative risk (RR) among women in the highest 
quintile compared to the lowest quintile of Brassica vegetable consumption, median 
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serving of 1.5 per day, was an RR of 0.58 (95% CI, 0.42-0.79) (Terry et al. 2001).  In 
contrast, a case-control study by Lissowska et al. (2008) found little or no protective 
effect of Brassica vegetables on breast cancer risk. 
 Until recently, prospective cohort studies have yielded inconsistent results 
between the association of Brassica vegetable consumption and breast cancer risk 
(Smith-Warner et al. 2001; Van Gils et al. 2005; Agurs-Collins et al. 2009).  Three 
prospective cohorts of major interest are the Black Women‟s Health Study (Boggs et al. 
2010), and two papers published on the European Prospective Investigation into Cancer 
and Nutrition (EPIC) (Masala et al. 2012; Cottet et al. 2009).  The Black Women‟s 
Health Study consisted of 51,928 AA women aged 21 to 69 years of age (Boggs et al. 
2010).  They found that AA women who consumed more fruits or vegetables were more 
likely to be older, to live in the northeastern and western regions of the United States, be 
physically active, nonsmokers, and take multivitamins (Boggs et al. 2010).  Boggs et al. 
(2010) also found that education level was positively associated with vegetable 
consumption.  This study (Boggs et al. 2010) found an inverse association between breast 
cancer risk and Brassica vegetable intake; incidence ratios for 1-2, 3-5, and ≥6 servings 
per week compared with <1 serving per week were 0.94 (95% CI: 0.80- 1.11), 1.01 (95% 
CI: 0.84-1.21), and 0.80 (95% CI: 0.65-0.99), respectively.  In premenopausal women, 
this association was stronger when comparing ≥6 servings per week compared with <1 
serving per week (IRR, 0.59; 95% CI: 0.42-0.83); conversely, there was no evidence of 
an association among postmenopausal women (Boggs et al. 2010). 
The EPIC study in Italy (Masala et al. 2012) was a large prospective cohort study 
of 31,000 women aged 36 to 64 years of age.  A large variety of vegetables and fruit are 
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consumed by Mediterranean populations, so this made Italy a favorable setting to 
evaluate the association of these foods and breast cancer risk.  Overall, an inverse 
association between the consumption of total vegetables and breast cancer risk emerged; 
in particular, they observed an inverse association in the increased intake of leafy 
vegetables (e.g., salad greens, chard, spinach, and other leafy greens) (highest vs. lowest 
quintile HR, 0.70; 95%CI, 0.57-0.86), fruiting vegetables (peppers, artichokes, aubergin, 
courgette, green beans, fennel, celery) and raw tomatoes (Masala et al. 2012).  However, 
there was no evidence of an inverse association between cabbages (broccoli, brussel 
sprouts, cauliflower, black cabbage and savoy cabbage) and breast cancer risk when 
comparing the highest vs. lowest quintile (HR, 0.91; 95% CI: 0.74-1.12) (Masala et al. 
2012). Thus, while generally supportive of in inverse association between Brassica 
vegetables and breast cancer, the epidemiologic literature has not always yielded strong, 
consistent associations.  Null findings could be related to a narrow range in intake of 
Brassica vegetables in the populations that were studied (Hebert et al. 1991) or 
measurement error from the dietary assessment instrument used (usually food frequency 
questionnaires with known measurement error) (Schatzkin et al. 2003). 
PART II:  Breast Cancer and 2:16α-OHE  
   In general, studies have shown that the estrogen metabolism pathways that favor 
2-OHE metabolites over 16α-OHE metabolites are associated with the reduced risk of 
developing invasive breast cancer, especially in postmenopausal women (Schneider et al. 
1982; Coker et al. 1997; Muti et al. 2000; Taioli et al. 1996; Meilahn et al. 1998; Fowke 
et al. 2003; Im et al. 2009); however, there have also been a few papers that have found 
no association between breast cancer risk and the 2:16α-OHE ratio (Lissowska et al. 
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2008; Obi et al. 2011; Arslan et al. 2009; Ursin et al. 1999; Ursin et al. 1997; Cauley et 
al. 2003).
 
 In some studies, the ratio was found to be significantly lower in AA women 
than EA women (Sowers et al. 2006; Taioli et al. 1996; Coker et al. 1997).  In a case-
control study (74 cases, 58 controls) conducted among EA and AA pre and 
postmenopausal women by Coker et al. (1997), it was found that AA women had 
significantly lower 2-OHE (adjusted for creatinine) levels than EA; though not 
significant, AA women also had lower mean levels of 2:16α-OHE ratios than EA. These 
findings are consistent with the findings of a similar study conducted by Taioli et al. 
(1996), and are hypothesized to partially explain the racial disparities present in breast 
cancer mortality between AA and EA women. 
The first study to demonstrate a link between 2:16α-OHE ratio and breast cancer 
risk was published in 1982 by Schneider et al.  In a comparison of serum estradiol 
metabolites in 33 women diagnosed with breast cancer to 10 healthy women, they found 
that the serum 16α-OHE levels of breast cancer patients were 50% higher than the 
controls; 2-OHE levels were similar between the two groups (Schneider et al. 1982).  
Since then, other studies have gone on to demonstrate that the 2:16α-OHE ratio is 
significantly lower in breast cancer cases compared to controls in premenopausal women 
(Muti 2000), postmenopausal women (Zheng 1998; Kabat 1997; Meilahn et al. 1998) or 
both ( Ho 1998; Kabat et al. 2006; Fowke et al. 2003). 
In a nested case-control study of 676 women conducted by Muti et al. in Italy 
(2000), premenopausal women had a 42% decrease in breast cancer risk for the highest 
quintile of 2:16α-OHE ratio compared to the lowest quintile (adjusted OR, 0.58; 95% CI: 
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0.25-1.34). There was no association among postmenopausal women when comparing 
the highest vs. lowest quintile (adjusted OR, 1.29; 95% CI: 0.53-3.10) (Muti et al. 2000). 
In a large cohort study of 5,104 pre and postmenopausal women by Meilahn et al. 
(1998), women in the highest tertile of the urinary 2:16α-OHE ratio were 30% less likely 
to develop breast cancer over follow-up periods of up to nine years.  These results were 
not consistent with two case-control studies conducted by Ursin et al. (1997 and 1999) 
that showed no significant relationship between the 2:16α-OHE ratio and breast cancer 
risk among postmenopausal women; however, this could be because the sample sizes of 
both of these studies were not large enough to yield statistical significance (142 
postmenopausal women in the 1999 study and 48 postmenopausal women in the 1997 
study) (Ursin et al. 1997; Ursin et al. 1999). 
Both Kabat et al. (2006) and Fowke et al. (2003) demonstrated through case-
control studies that 2:16α-OHE ratios are associated with breast cancer risk in both pre 
and postmenopausal women.  Kabat et al. (2006) used the Long Island Breast Cancer 
Study Project to assess the association of the urinary estrogen metabolites 2-OHE, 16α-
OHE, and their ratio, among 269 invasive breast cancer cases, 158 in situ breast cancer 
cases and 326 controls.  They found that 2:16α-OHE was inversely associated with breast 
cancer risk among premenopausal women and found a weaker reduction in risk among 
postmenopausal women; (Kabat et al. 2006).  These results were similar to what Fowke 
et al. (2003) found in a case-control among Chinese women living in Shanghai (n=220); 
however, they also compared pre versus post treatment urine collection among the breast 
cancer patients.  Subjects with higher 2:16α-OHE ratios were less likely to be diagnosed 
with breast cancer, but only when the urine sample was collected prior to any breast 
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cancer treatment (Fowke et al. 2003).  Conversely, breast cancer cases among subjects 
whose urine was collected after treatment yielded significantly higher 2:16α-OHE ratios 
(Fowke et al. 2003).  The cross-study differences that Fowke et al. (2003) found in the 
urine collection time periods may help to explain the inconsistencies that are observed in 
the association between breast cancer risk and 2:16α-OHE ratio. 
A more recent study by Im et al. (2009) explores whether average urinary 
estrogen metabolites among breast cancer “high-risk women” could be a predictor of 
future breast cancer development; furthermore, they also addressed whether urinary 
2:16α-OHE ratio may be linked to specific epidemiologic risk factors.  The study 
population consisted of 77 high-risk women, 30 breast cancer patients and 41 controls 
(Im et al. 2009).  The median 2:16α-OHE ratios differed significantly among the groups, 
with the high-risk (1.76±2.33)  and breast cancer (1.29±0.80) group ratios both being 
significantly lower when compared to controls (2.47±1.14; P=0.0001);  while no 
significant difference was observed between the high-risk and breast cancer group (Im et. 
al. 2009).  The same pattern of median 2:16α-OHE ratios was observed among 
postmenopausal women, with the controls having higher median levels than both high-
risk and breast cancer group; however, the differences were non-significant (Im et al. 
2009).  Moreover, there was a significant association observed between 2:16α-OHE ratio 
and alcohol use in the groups; there was no association observed between smoking or age 
and 2:16α-OHE ratio (Im et al. 2009).  Overall, this study shows that 2:16α-OHE ratios 
have been found to be significantly lower in women at high-risk for developing breast 
cancer when compared to healthy women, suggesting that lower 2:16α-OHE ratios may 
be used as biomarkers and prognostic indicator in high-risk populations.  Additionally, 
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further understanding of the urinary estrogen metabolite ratios may help lead to new 
breakthroughs in terms of risk reduction strategies. 
PART III:  Brassica Vegetables and 2:16α-OHE  
Estrogen is metabolized along two competing pathways which are 2-OHE and 
16α-OHE urinary metabolites.  Brassica vegetables play an important role in this overall 
mechanism by modulating the activity of cellular enzymes that are responsible for the 
production of these estrogen metabolites (Maizes 2005).  Indole-3-carbionol (I3C) is a 
dietary indole found in Brassica vegetables (e.g. cabbage, broccoli, kale, turnips, 
collards, cauliflower, and Brussels sprouts); studies have demonstrated that  I3C directly 
induces the production of 2-OHE, known as “good estrogen” (Lord et al. 2002; Nguyen 
et al. 2010; Laidlaw et al. 2010; Dalessandri et al. 2004).  Furthermore, the major in vivo 
product of I3C is 3,3‟–diindolylmethane (DIM) which is thought to be the major mediator 
of chemopreventive and chemotherapeutic effects of I3C (Dalessandri et al. 2004; Kelloff 
2000).  I3C and DIM are responsible for the metabolism of estrone to form the estrogen 
metabolite 2-OHE (estrogen receptor antagonist) at the expense of 16α-OHE (estrogen 
receptor agonist) (Dalessandri et al. 2004).  The enzymes responsible for the conversion 
of estrone to either 2-OHE or 16α-OHE are cytochrome P450 (CYPs) (Dalessandri et al. 
2004).  In particular, CYP1A1 favors the metabolic pathway of 2-OHE, which is 
considered protective (Schneider 1984; Fowke 2000; Wong 1997; Dalessandri et al. 
2004); conversely, the production of 16α-OHE can lead to the stimulation of cell 
proliferation (Schneider et al. 1982; Kabat 1997; Dalessandri et al. 2004).   
Two studies by Bradlow et al. (1994) and Laidlaw et al. (2010) examined the role 
of I3C on the excretion of 2-OHE and found a significant increase in the 2-OHE urinary 
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metabolite levels.  Bradlow et al. (1994) conducted a randomized clinical trial among 60 
women who were recruited from a high-risk registry of the Strang Cancer Prevention 
Center.  The women were randomized into one of 3 arms: 400mg/day of I3C, 20g/day of 
α-cellulose, or placebo arm (Bradlow et al. 1994).  From baseline to 3-months, there was 
a significant change in the mean 2:16α-OHE (0.72 to 1.19, respectively) in the arm that 
received 400mg/day of I3C (Bradlow et al. 1994).  Within this same I3C arm, there were 
3 women who had no change in these ratios over the course of the study (2 had very low 
metabolite ratios to begin with and one had a large ratio to begin with); these women may 
need larger doses of I3C to induce a response (Bradlow et al. 1994).  Overall, Bradlow et 
al. (1994) demonstrated that I3C can directly increase the 2:16α-OHE ratio.  Laidlaw et 
al. (2010) demonstrated similar results in a double-blind, placebo-controlled, parallel 
study among 98 pre and postmenopausal women who were placed into one of two arms.  
One arm consisted of premenopausal women not using hormonal contraceptives, with the 
other arm consisting of postmenopausal women not receiving hormone replacement 
therapy (HRT); each arm was then randomized to receive either the placebo (supplement 
consisting of microcrystalline cellulose) or treatment (supplements contained 200 mg I3C 
and 10 mg HMR lignans) for a period of 28 day (Laidlaw et al. 2010).  In premenopausal 
women, the treatment group resulted in a significant increase in the urinary 2-OHE 
concentrations (6.34 to 13.29; P=0.003) and in the 2:16α-OHE ratio (0.88 to 1.66; 
P=0.016) (Laidlaw et al. 2010).  Among postmenopausal women, the treatment group 
only showed a significant increase in the urinary 2-OHE concentration (9.22 to 17.37; 
P=0.035) but no significant change in the 2:16α-OHE ratio (4.54 to 5.40; P=.387) 
(Laidlaw et al. 2010).  The placebo group biomarkers in both pre and postmenopausal 
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women exhibited no significant change in mean concentration levels (Laidlaw et al. 
2010). 
In contrast to dosing with I3C directly, there have been several studies that have 
demonstrated that Brassica vegetable intake can modify the 2:16α-OHE ratio (Kall et al. 
1997; Fowke et al. 2000; Morrison et al. 2009).  Kall et al. (1997) found that the average 
2:16α-OHE ratio significantly increased by 29.5% (p<0.05) after a group of 18 volunteers 
increased their consumption of broccoli to 500g/day for 12 days.  Though this was a very 
short experimental study with no control group, the results support the idea that Brassica 
vegetables can increase the 2:16α-OHE ratio.  There have been more recent randomized 
clinical trials that have shown these same consistent results but over a longer period of 
time (Morrison et al. 2009; Fowke et al. 2000).  In an intervention study by Morrison et 
al. (2009), 12 out of the 13 premenopausal women had a baseline 2:16α-OHE ratio that 
was below the recommended 2.0 cutoff; however, 11 of the 13 women showed positive 
increases in their ratios with three of the subjects who had the lowest baseline ratios 
having an average increase of 500% at the completion of the 3-month study (added 3.6 g 
of powdered organic Brussels sprouts and organic kale to diet) (Morrison et al. 2009).  
The overall average 2:16α-OHE ratio improvement was 168%, with the increase being 
due to increase levels of 2-OHE in 11 of the subjects and in 9 subjects due to the decrease 
in the 16α-OHE excretion levels (Morrison et al. 2009).  A paired sample t-test analysis 
comparing the initial and final 2:16α-OHE ratios for all 13 subjects showed a significant 




  Fowke et al. (2000) demonstrated similar results with an intensive intervention 
design over a 4-week period to increase Brassica vegetable consumption to at least 
70mg/day (Fowke et al. 2000).  At baseline, Brassica vegetable consumption on average 
was only about
 
9g/day with 2:16α-OHE ratio at 2.27 and after the intervention these, 
respectively, were 193g/day and 2.38, which was about a 20-fold increase in grams of 
Brassica vegetable consumption among these women (Fowke et al. 2000). In the crude 
analysis, there was no significant increase in the urinary 2:16α-OHE ratio associated with 
increased consumption of Brassica vegetables; however, when adjustment for other 
dietary parameters were applied, Brassica vegetable consumption was associated with a 
statistically significant increase in the 2:16α-OHE ratio, in that each 10g/day increase in 
Brassica vegetable consumption led to an increase of about 0.08 (95% CI, 0.02-0.15) in 
the 2:16α-OHE ratio (Fowke et al. 2000).  It was also noted, that the 2:16α-OHE ratio 
shift appeared to be sensitive to the specific type of vegetables that were consumed 
during the intervention (Fowke et al. 2000).  When multivariable model analysis was 
performed on the amount of broccoli, cabbage, Brussels sprouts, or other Brassica 
vegetable simultaneously, an increase of 10g of cabbage was found to be associated with 
an increase of 0.07 (95% CI, -0.04-0.19) in the urinary 2:16α-OHE levels, whereas an 
increase of 10g of broccoli was associated with only an increase in 0.01 (95% CI, -0.09-
0.11) (Fowke et al. 2000).  Brassica vegetables that were lightly cooked or raw appeared 
to cause an equal shift in the 2:16α-OHE ratio levels for each 10g/day of vegetables 
(cooked: 0.03; 95% CI, 0.03-0.10 and raw: 0.03; 95% CI, -0.08-0.13) (Fowke et al. 
2000).  
 
 In conclusion, a shift of 0.08 in the 2:16α-OHE ratio for every 10g/day of 
Brassica suggests that the population would need to increase Brassica vegetable 
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consumption between 12.5g/day to 75g/day in order to cause a direct, favorable shift in 
movement of the 2:16α-OHE ratio levels to affect the causal mechanism leading to breast 





MATERIALS AND METHODS 
 
Study Population and Setting 
 Postmenopausal women who resided in the standard metropolitan statistical area 
(SMSA) around the Columbia, South Carolina area were recruited between April 2002 
and September 2003.  Through advertisement, a total of 138 women were recruited 
through a telephone screening interview from two breast care clinics under Palmetto 
Health (the major health care provider in the area) and from a local television and 
newspaper study briefing.  Women were considered eligible if they were postmenopausal 
(defined as >1 year since last menstrual cycle), willing to be randomized, willing to 
provide post-intervention urine samples, were not on any special diet or weight-loss 
program, and had not lost over five pounds in the past year.  Women were considered to 
be ineligible if they were not on a stable, fixed dose of medications [including hormone 
replacement therapy (HRT)], were diagnosed with a malignancy (other than melanoma or 
breast cancer) in the past five years, were on thyroid medications, had a health condition 
that would limit their participation, or if they consumed over 2 alcohol-containing drinks 
per day.  Due to the older age of the sample population it was not possible to exclude 
women who were using diabetic medications, using antibiotics, or diuretics.  Instead, 
women were asked to consistently ingest any medications on a stable, fixed dose during 




(n = 51) 
 
Control 
(n = 45) 
 
From the eligible sample of women, 109 women (79.0%) met with study 
personnel to review the study procedures, provide a signed informed consent and 
complete all study questionnaires, anthropometric measurements and biological samples 
that are described below.  During the baseline clinic visit, 84 of the eligible women 
(77.1%) completed the baseline questionnaire.  After the second clinic visit, 65 women 
had provided urine samples from both the first and second clinic visit.  In total, 14 
eligible women withdrew before ever attending the first clinic, 28 women dropped after 
the first clinic, 2 women had incomplete baseline questionnaires, and one woman failed 
to have a 24-hour dietary recall performed.  Therefore, the study population that was used 
for analysis consisted of 64 women who attended both clinic visits with complete urine, 
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Study Procedures & Sample Collection 
The study protocol was approved by USC and Palmetto Health institutional 
review boards.  A written, signed informed consent was obtained during the initial 
screening visit from all of the women who were considered eligible to participate in the 
study.   
Baseline, Body and Biological Sample Collection 
A baseline questionnaire assessing demographics, general smoking and alcohol 
exposure, reproductive health history, and past week physical activity was completed at 
the first clinical visit.  Furthermore, at both clinics anthropometric data (including height, 
weight, body circumference) and biological samples were collected (Figure 3.2).  Waist  
 Figure 3.2:  Overview of Study Design 
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circumference was measured by a tape measure that was held tightly in a horizontal 
position at the lower rib margin after the participant removed any heavy outerwear.  
Similarity, abdominal circumference was taken midway between the lower rib and iliac 
crest, and hip circumference was measured around the widest part of the hips.  Percent 
body fat was measured using a bioelectrical impendence analyzer (Quantum II Model, 
RJL Systems, Clinton Twp., MI).  Total body resistance and reactance were recorded to 
the nearest ohm by study personnel to calculate the resistance index which is defined as 
the height
2
 divided by the total body resistance.   
An overnight fasting urine sample was provided by participants in cups that 
contained a preservative, ascorbic acid as 125mg to 100ml of urine, to prevent oxidation.  
It was unnecessary to perform 24-hour urine collections because previous data has shown 
that 24-hour average expressed per milligram expressed creatinine was not significantly 
different from first-morning expressed creatinine values.  This alleviated participant 
burden as well.  The urine was placed on ice (4°C) and then transferred to the lab to be 
immediately centrifuged.  Within six hours of the urine collection, the samples were 
aliquoted into 1ml cryovials and placed into long-term storage at -80°C. 
Randomization 
The women were randomized into one of two arms, non-intervention (control) 
group or intervention group during the first clinic visit by using a fixed randomization 
scheme with a block size of four.  We blocked on the day of clinic and the small block 
size was meant to reflect the average number of women who actually attended the first 
clinic visit on the same day.  The women randomized into the control arm were asked to 
maintain their usual dietary habits for the duration of the study period.  After completion 
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of the second clinic, those in control arm were invited to attend the cooking classes and 
receive all the intervention materials.   
Intervention 
Participants randomized into the dietary intervention arm were offered nine 
classes that were led by trained study dietitians over a three-week intervention period.  
The study protocol required that the participants had to attend between six to nine classes.  
During these classes, the registered dietitian explained study goals, scientific rationale, 
provided a recipe book, and administered cooking classes.  The women were advised to 
consume an ample number of Brassica vegetables daily at home.  A point system was put 
in place to assign a greater number of points to less commonly consumed Brassica 
vegetables in hopes of encouraging women to try new vegetables that belonged to the 
Brassica family.  Women were asked to attain ten points.  An ample amount of fresh, 
locally grown Brassica vegetables were given to study participants each week. 
The primary objective of the cooking classes was to encourage women to increase 
their Brassica vegetable consumption as part of a healthy diet.  In order to help 
participants overcome the challenge of changing their eating habits, women were shown 
how to incorporate more Brassica vegetables into their diet through cooking 
demonstrations that were conducted in each class and gave participants the opportunity to 
prepare and sample recipes that called for Brassica vegetables as a main ingredient.  Each 
cooking demonstration was provided in a way to highlight a variety of cooking 
techniques to help participants add variety to their meals and help increase compliance to 
the diet.  The majority of the meals prepared during the demonstrations included 
vegetables in the form of slaws, salads, stir-fries and dips to encourage the eating of raw 
27 
 
or lightly cooked vegetables, in order to provide the most nutrients to them as possible.  
To maintain uniformity, the dietitians were instructed in pre-class preparation, class 
activities, suggestions for cooking demonstrations, taste-testing, and discussion of 
facilitation.  In order to encourage class participation and attendance, the intervention 
classes were structured in a way to provide instructions on increasing Brassica vegetable 
consumption as well as incorporate other healthy eating principles into the intervention.  
Participants were provided with written instructions as well as discussed in class how to 
read food labels, increase fiber, decrease fat, incorporate alternate foods (e.g., soy 
products), use herbs and spices, the importance of minerals and vitamins, and how to 
modify recipes.  Each principle overall was tied into the message of increasing Brassica 
vegetable consumption.  For example, participants discussed how they could modify 
some of their favorite recipes with inclusion of or increase in Brassica vegetables.  The 
strategies used to alter food patterns included eliminating or adding foods to the baseline 
diet, modifying or substituting foods, and overcoming potential barriers including 
structural changes i.e., food availability and preparation at home, modifying recipes, 
portion sizes.  Women were not given any advice on how to reduce total food 
consumption or to count calories.  The dietitians also provide individual level dietary 
counseling to increase the consumption of Brassica vegetables. 
Dietary Assessment 
Diet was assessed on all participants through four unannounced 24-hour dietary 
telephone recall interviews (24HR), two weekdays and two weekend days, during each of 
the three study periods for a total of twelve interviews by the end of the nine-week study 
period.  The four recalls were respectively conducted in the pre-intervention period 
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(weeks 1-3), intervention period (weeks 4-6), and post-intervention period (weeks 7-9).  
These interviews were administered by trained registered dietitians using a structured 
interview protocol.  The recalls were administered on non-consecutive days to obtain a 
representative sample of a participant‟s actual dietary intake.  Additionally, two other 
methods were used to track Brassica vegetable consumption during the intervention 
period.  Participants randomized to the intervention arm were given a food diary to 
maintain during the intervention; however, these diaries were not collected for data 
analysis purposes.  To roughly assess the average servings of commonly consumed foods 
containing phytoestrogens, all participants were required to complete a brief fruit and 
vegetable questionnaire at both clinic visits.  However, this questionnaire was not 
analyzed in this since the 24HR provides a more accurate depiction of foods consumed 
during the study. 
The Nutrition Data System (NDS version 34) interactive software developed by 
the Nutrition Coordinating Center, University of Minnesota (Minneapolis, MN) was used 
to collect and analyze the data for nutrient intake (NCI Food Database and Nutrient 
Database version 33), (Feskanich et al. 1989).  A two-dimensional food proportion poster 
helped participants visualize and estimate food portions consumed during the previous 
24-hour period. 
 It is well-known that longer cooking may inactivate the enzyme myrosinase 
which is responsible for breaking down glucosinolates into their active forms 
(isothiocyanates, nitriles, thiocynates, indoles) and that these active forms will be 
absorbed into the cooking water because they are hydrophilic (Getahun et al. 1999).  
Therefore, we controlled for cooking method in analysis by dichotomizing the 
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preparation of each vegetable into either a raw or cooked form.  The NCI food database 
items that listed the preparation method as “raw” (and given a value of “2”) for data 
analyses including those classified as raw, blanched, or stir-fried.  All other preparation 
methods (i.e., cooked, soup) were categorized as “cooked” (and given a value of “1”).  
Additionally, since both servings of Brassica vegetables and cooking methods were 
thought to be altered by the dietary intervention and would possibly affect estrogen 
metabolite levels, we combined these two variables by multiplying the vegetable serving 
and cooking method to obtain a single variable that reflected both serving and cooking 
methods. 
Urine Collection and Assays 
The analysis of the urinary estrogen biomarker was conducted using ELISA.  The 
estrogen assays were conducted at the University of South Carolina Cancer Center 
laboratory by Dr. Xie, who was blinded to the identity and assignment of the participants.  
The assays were performed in duplicate batches of 30 to 40 samples in a random order 
over a one-week period using the ESTRAMET 2/16 enzyme immunoassay kit 
(Immunacare, Bethlehem, PA).  To ensure quality control a sample of participants who 
enrolled in the study and provided a urine sample at only one clinic were included in each 
batch of analysis.  Dr. Xie used these samples in order to monitor the consistency of lab 
values from batch to batch.  The absorbance values from six standards that were included 
in the ELISA kit were used to derive a standard curve.  In each batch, samples that had a 
coefficient of variation (CV) indicating a very dilute or concentrated sample were re-
assayed with a more appropriate dilution. 
30 
 
The total urine output was not known (i.e., 24-hour urine samples were not 
collected); therefore, creatinine levels also were measured in order to adjust for 
differences due to urine concentration.  The creatinine levels were measured using the 
Jaffe reaction with the Cayman Chemical Creatinine Kit (Ann Arbor, MI).  The urinary 
estrogen metabolite levels in each sample were then standardized by dividing estrogen 
metabolite values (ng/ml) by creatinine levels (mg/dl).  The urine samples were 
considered unavailable if women did not provide urine samples at both clinical visits or if 
urine sample dilutions were not in the linear portion of the standard curve even with 
repeated assays.  Samples that yielded values that were extreme or on either the 2-OHE 
or 16α-OHE assays were examined as possible outliers during statistical analysis. 
Definition of Variables 
 The primary exposure of interest was Brassica vegetable consumption which was 
measured as a continuous variable.  This was defined by computing the mean and median 
of each Brassica vegetable serving size (broccoli, green or white cabbage, Brussels 
Sprouts, cauliflower, kale rutabaga, red cabbage, collard greens, savoy cabbage, Chinese 
cabbage, turnip greens, turnip, mustard greens, and radish) separately and then computing 
a total mean and median of them all combined.  For analysis, the four 24HRs in each 
three-week cycle were averaged for each participant to provide the best estimate of 
Brassica vegetable consumption for each study period.  The intervention and control 
arms were then analyzed to see if there was a mean difference between the primary 
outcomes of the 2-OHE, 16α-OHE or 2:16α-OHE. 
 For the second aim, the primary exposure of interest was baseline Brassica 
vegetable consumption (defined as mean Brassica vegetable consumption pre-
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intervention), and women were stratified by baseline diet to examine whether the effect 
of the intervention on the 2:16α-OHE ratio differed by baseline intake of Brassica 
vegetables.  
 For the third aim, the primary outcome was the mean 2:16α-OHE ratio, and the 
effect of the intervention was examined stratified by race (defined as EA or AA) or breast 
cancer survivorship status [breast cancer compared to women without breast cancer]. 
Covariates 
 Demographic information was obtained from the baseline questionnaire.  Self-
reported race was defined as European American (EA) or African American (AA).  
Education level was defined as three categories: less than high school, high school 
completed and any college.  Living status was defined as two categories: living alone or 
not living alone.  Employment history was defined by three categories: yes full time, yes 
part time, and no.  All other variable were dichotomous (yes/no): smoking exposure 
(defined as being exposed in the past week to cigarette, cigar, or pipe smoke in or outside 
of the workplace), alcohol exposure (defined as consumption of alcohol within the past 
week), ever been pregnant, physical activity (defined as have you played a sport or other 
physically active activity during the past week), and breast cancer survivorship status; or 
continuous: age, , current weight (in pounds), number of pregnancies, body mass index 
(BMI = weight (kg) / height (m)
2
), and percent body fat.  
Statistical Analysis 
 All analyses were performed using SAS statistical software version 9.3.  
Preliminary descriptive statistics of the study population was generated, including means, 
medians, and standard deviations for continuous variables, and frequencies for the 
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categorical variables. Data transformations were applied to variables as necessary to meet 
the requisite normality assumptions. Tests for statistical significance was assumed as a 
Type I error rate of 5% and be based on a two-sided test (p<0.05 was considered 
statistically significant).  
 Aim 1:  We determined the dietary intake of Brassica vegetables and other dietary 
factors (e.g., energy, macronutrients, fiber) by computing the mean and median serving 
size or gram amount within each food group or nutrient from the 24HR-derived dietary 
data that was collected at each of three time points (pre-, during and post-intervention).  
Data for individual ingredients was collected for mixed dishes so that these foods could 
be added into the appropriate food group.  Nutrients from supplements were also added to 
the dietary intake estimates. For analysis, the four 24HR in each three-week cycle was 
averaged for each participant to provide the best estimate of dietary intake for each time 
point. We determined the mean, median and standard deviation of the outcome variables 
(2-OHE, 16α-OHE and2:16α-OHE) at each time point (baseline and post-intervention), 
as well as the mean change between baseline and post-intervention. Paired t-tests were 
used to examine whether the change in 2:16α-OHE  or the individual metabolites was 
significantly different from zero within each intervention arm. We used the SAS GLM 
procedure using post-intervention estrogen metabolite levels as the outcome and the 
intervention status as the exposure with adjustment for baseline estrogen metabolite 
levels.  
 Aim 2: To test for intervention effect differences between high and low 
consumers of Brassica vegetables at baseline, we used the SAS GLM procedure with the 
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2:16α-OHE ratio as the outcome and the intervention assignment as the exposure, using a 
by statement to stratify by baseline dietary Brassica intake. 
 Aim 3:  Similarly, the model testing differences by race and survivorship used 
these as predictors rather than intervention assignment.  We used the SAS GLM 
procedure with a by statement for race or breast cancer survivorship status to stratify by 
these variables.   
These analyses examined potential confounders, including: age, anthropometric 
characteristics (i.e., BMI, percent body fat), race/ethnicity, breast cancer survivorship 
status, reproductive factors, smoking, alcohol, physical activity, fat intake and energy 
intake.  These potential confounders are hypothesized to be related to both Brassica 
vegetable intake and the urinary estrogen metabolites.   
Potential confounding variables and effect-modifiers were chosen from the 
literature   and entered hierarchically into the proc GLM model; those with highest p-
value were removed in a stepwise procedure. .  Each possible demographic and dietary 
confounder was examined first for normality and transformed before entering into the 
multiple regression analyses if high skewness (absolute value > |0.3|) or high kurtosis 
(absolute value >|1.0|) were evident. Variables that were found to be significant 
predictors and related to both the predictor (Brassica vegetable intake) and outcome 
(estrogen metabolites) were added to the final model as confounders.  Analyses were also 
repeated excluding outliers and confounders to examine differences in the model's 







Descriptive Characteristics of the Study Population 
 Descriptive characteristics of the study population at baseline are shown in Table 
4.1.  At baseline, there were no significant differences between the intervention and 
control arms in anthropometric, demographic, or clinical measures.  Women were on 
average 61.0 ± 8.8 years of age, tended to be classified as overweight with an average 
BMI of 29.0 ± 5.6 kg/m
2
 and an average percent body fat of 39.5 ± 5.6.  The majority of 
the women had not been exposed to smoke within the past week (75.0%) and exercised 
regularly (89.4%).  More than half of the women had consumed alcohol within the past 
week (64.6%). Most of the women were college educated (77.3%) and married (65.2%) 
with 41.5% employed full-time and 43.1% unemployed.  AA women comprised 28.8% of 
the study population (8 control and 11 intervention participants).  About 90% of the 








(n = 35) 
All Participants 





Age 61.9 (9.1) 60.3 (8.7) 61.0 (8.8) 0.5 
BMI, kg/m
2
 28.7 (6.2) 29.3 (5.0) 29.0 (5.6) 0.6 
Percent Body Fat 38.9 (6.6) 28.7 (4.6) 39.5 (5.6) 0.4 
Weight, lbs 164.1 (39.3) 170.6 (33.0) 167.6 (36.0) 0.5 
Number of pregnancies 2.2 (1.0) 2.6 (1.3) 2.4 (1.2) 0.3 
     
N (%) 
Race     
European American 23 (74.2%) 24 (68.6%) 47 (71.2%)  
African-American 8 (25.8%) 11 (31.4%) 19 (28.8%) 0.6 
     
Education     
≤ High School 8 (25.8%) 7 (20.0%) 15 (22.7%)  
>High School 23 (74.2%) 28 (80.0%) 51 (77.3%) 0.6 
     
Employment Status     
Full Time 14 (46.7%) 13 (37.1%) 27 (41.5%)  
Part Time 4 (13.3%) 6 (17.1%) 10 (15.4%)  
Unemployed 12 (40.0%) 16 (45.7%) 28 (43.1%) 0.5 
     
Married/Living with Partner     
Yes 18 (58.1%) 25 (71.4%) 43 (65.2%)  
No 13 (41.9%) 10 (28.6%) 23 (34.9%) 0.3 
     
Smoking Exposure     
Yes 8 (27.6%) 8 (22.9%) 16 (25.0%)  
No 21 (72.4%) 27 (77.1%) 48 (75.0%) 0.7 
     
Regular Alcohol Consumption     
Yes 21 (67.7%) 21 (61.8%) 42 (64.6%)  
No 10 (32.3%) 13 (38.2%) 23 (35.4%) 0.6 
     
Physical Activity     
Regular Exercise 28 (90.3%) 31 (88.6%) 59 (89.4%)  
No Regular Exercise 3 (9.7%) 4 (11.4%) 7 (10.6%) 0.8 
     
Ever Been Pregnant     
Yes 25 (86.2%) 31 (93.9%) 56 (90.3%)  
No 4 (13.8%) 2 (6.1%) 6 (9.7%) 0.3 
     
Breast Cancer Survivor     
Yes 8 (25.8%) 10 (28.6%) 18 (27.3%)  
No 23 (74.2%) 25 (71.4%) 48 (72.7%) 0.8 
1
Chi-square test (p-value) 
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Differences in Actual Intake between Baseline and Mid-Intervention by Treatment 
Status 
Table 4.2 shows the change in mean intake of nutrients, fruit and vegetables by 
treatment group from baseline to mid-intervention (median differences shown in Table 
4.3).  The p-value represents whether the change in the control group is different from the 
change in the intervention group. Both treatment groups had non-significant decreases in 
mean energy intake (control -47.4 ± 419.3 kcal/d; intervention -82.8 ± 308.6 kcal/d), 
protein intake (control -7.0 ± 25.1 g/d; intervention -3.4 ± 17.5 g/d) and fat intake 
(control -3.2 ± 22.2 g/d; intervention -2.3 ± 16.1 g/d), and non-significant changes in 
mean carbohydrate intake (control 2.2 ± 48.0 g/d; intervention -7.3 ± 44.4 g/d).  Soluble 
fiber mean intake significantly increased only in the intervention group (control -0.1 ± 
2.0 g/d; intervention 2.0 ± 2.0 g/d) with an average intake of 6.8 ± 2.1 g/d in intervention 
compared to 4.9 ± 1.8 g/d in controls during the intervention. Dietary fiber mean intake 
significantly increased in both treatment groups (control 0.3 ± 5.9 g/d; intervention 3.6 ± 
5.3 g/d).   
One vegetable serving was calculated as 0.5 cups of raw or cooked vegetables. 
Compared to baseline levels, total mean vegetable intake increased significantly only in 
the intervention group (control -0.5 ± 1.6 srv/d; intervention 2.4 ± 1.8 srv/d) with 
participants in the intervention consuming an average of 5.2 ± 1.6 srv/d compared to 
control participants consuming 2.8 ± 1.4 srv/d mid-intervention.  Similarly, Brassica 
vegetable intake only significantly increased in the intervention group (control -0.2 ± 0.6 
srv/d; intervention 2.6 ± 1.5 srv/d) with intervention participants consuming on average 
3.0 ± 1.5 srv/d compared to controls only consuming on average 0.5 ± 0.6 srv/d  mid-
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intervention.  Mean fruit intake did not change significantly in either group (control 0.1 ± 
1.0 g/d; intervention -0.3 ± 1.0 g/d; p=0.14). 
Table 4.2: Differences in Actual Mean Intake between Baseline and Mid-Intervention by 




































































































































































































































One serving is equivalent to 0.5 cups of raw or cooked vegetables 
2
Difference between the means of baseline and during intervention. 
*represents significant p-values (< 0.05) which is testing whether the change in the control group is 







Table 4.3: Differences in Actual Median Intake between Baseline and Mid-Intervention by 





































































































































































































































One serving is equivalent to 0.5 cups of raw or cooked vegetables 
2
Difference between the median intake of baseline and during intervention. 
*represents significant p-values (< 0.05) which is testing whether the change in the control group is 
different from the change in the intervention group 
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Differences in Actual Intake between Post Intervention and Baseline by Treatment 
Status 
 
Table 4.4 also shows the difference in mean intake of nutrients, fruit and 
vegetables by treatment group between post intervention and baseline (median 
differences shown in Table 4.5). The p-value represents whether the change in the control 
group is different from the change in the intervention group.  Both treatment groups non-
significantly decreased mean energy intake (control -35.7 ± 438.2 kcal/d; intervention -
1137.4 ± 356.9 kcal/d), protein intake (control -3.7 ± 25.9 g/d; intervention -6.1 ± 19.1 
g/d), fat intake (control -1.8 ± 23.7 g/d; intervention -6.3 ± 23.0 g/d), and carbohydrate 
intake (control -0.5 ± 51.0 g/d; intervention -13.7 ± 59.7 g/d).  Soluble fiber mean intake 
significantly increased in the intervention group only (control -0.3 ± 1.7 g/d; intervention 
0.7 ± 2.0 g/d) with an average intake of 5.6 ± 1.5 g/d among intervention compared to 4.7 
± 1.6 g/d among controls. Dietary fiber mean intake increased only in the intervention 
group but was non-significant (control -1.3 ± 5.1 g/d; intervention 0.7 ± 5.0 g/d). 
One vegetable serving was calculated as 0.5 cups of raw or cooked vegetables. 
Compared to baseline levels, total mean vegetable intake increased significantly only in 
the intervention group (control -0.7 ± 1.5 srv/d; intervention 0.8 ± 1.6 srv/d) with 
participants in intervention consuming an average of 3.6 ± 1.5 srv/d compared to controls 
consuming 2.6 ± 1.1 srv/d post-intervention.  Similarly, Brassica vegetable intake only 
significantly increased in the intervention group, (control -0.3 ± 0.8 srv/d; intervention 
1.0 ± 1.1 srv/d) with intervention participants consuming on average 1.4 ± 1.3 srv/d 
compared to controls only consuming on average 0.4 ± 0.6 srv/d.  Fruit mean intake 
increased only in the control group (control 0.1 ± 1.1 srv/d; intervention -0.6 ± 1.1 srv/d) 
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with control participants consuming on average 1.6 ± 1.4 srv/d compared to intervention 
participants consuming 1.1 ± 0.9 srv/d.   
Table 4.4: Differences in Actual Mean Intake between Baseline and Post Intervention by 








































































































































































































































One serving is equivalent to 0.5 cups of raw or cooked vegetables 
2
Difference between the means of baseline and during intervention. 
*represents significant p-values (< 0.05) which is testing whether the change in the control group is 






Table 4.5: Differences in Actual Median Intake between Baseline and Post Intervention by 





































































































































































































































One serving is equivalent to 0.5 cups of raw or cooked vegetables 
2
Difference between the median intake of baseline and during intervention. 
*represents significant p-values (< 0.05) which is testing whether the change in the control group is 
different from the change in the intervention group 
 
Intervention Effects on Estrogen Metabolites by Treatment Status 
Table 4.6 displays unadjusted means and medians in 2-OHE, 16α-OHE and 
2:16α-OHE levels by treatment group between baseline and post intervention.  The 
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estrogen metabolite levels (ng/ml) were standardized by dividing by creatinine levels 
(mg/ml).  There were differences in the direction of the change in 2-OHE levels by 
treatment status with levels of 2-OHE increasing in both treatment groups (intervention 
mean change 0.2 ng/ml ± 2.6, p=0.4; control mean change -0.1 ng/ml ± 3.1, p=0.5) 
though these changes were not statistically significantly different between treatment 
groups. The levels of 16α-OHE non-significantly increased in the intervention group 
(mean change 0.3 ng/ml ± 2.2, p=0.5) and decreased in the control group (mean change -
0.1 ng/ml ± 2.2, p=0.9).  While 2:16α-OHE showed no mean change in the intervention 
or control group. 
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Intervention Change
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(1.7) -0.1 0.7 
1
Estrogen metabolite levels (ng/ml) were standardized by dividing by creatinine level (mg/ml). 
2
Within each arm, used Wilcoxen Signed Rank Test to see if the change was significantly 
different from zero. 
3
p-value represents within-group comparisons; no within-group change comparison was found 




Table 4.7 displays mean 2-OHE, 16α-OHE, and 2:16α-OHE at post intervention 
by treatment group. There was no statistically significant difference in 2-OHE between 
intervention and control group at post intervention after adjusting for baseline 2-OHE 
levels (12.5ng/ml vs. 12.2 ng/ml, respectively, p=0.9).  Similarly, no statistically 
significant difference was observed in 2:16α-OHE between intervention and control 
group after adjusting for baseline 2:16α-OHE levels (1.3 ng/ml vs.1.3 ng/ml, 
respectively, p=0.7).   












   
Intervention 12.5 (10.0, 15.6) - 
Control 12.2 (9.6, 15.4) 0.9 
16α-OHE, ng/ml 
3 
   
Intervention 9.4 (7.9, 11.2) - 
Control 9.0 (7.5, 10.8) 0.7 
2:16α-OHE ng/ml    
Intervention 1.3 (1.1, 1.6) - 
Control 1.3 (1.1, 1.6) 0.7 
1
Estrogen metabolite levels (ng/ml) were standardized by dividing by creatinine level (mg/ml). 
2
Logged values used for analysis 
3
LS means adjusted for baseline 2-OHE, 16α-OHE, and 2:16α-OHE, respectively. 
4
p-value represents the difference between intervention groups. 
 
Table 4.8 represents the final adjusted models for mean 2-OHE, 16α-OHE, and 
2:16α-OHE at post intervention by treatment group.  Potential confounders were assessed 
by starting with all potential confounders in the model and then removing them one-by-
one based on p-values; final model only yielding those that were found to be significantly 
associated with each estrogen metabolite outcome.   At post intervention, the differences 
in 2-OHE levels between intervention and control group were found to be statistically 
non-significant after adjusting for marital status, breast cancer survivorship status, age, 
and baseline percent fat mass (10.6 ng/ml vs. 8.7 ng/ml, respectively, p=0.4).  There was 
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statistically non-significant difference in 16α-OHE levels between intervention and 
control group at post intervention after adjusting for baseline percent fat mass (9.6 ng/ml 
vs. 8.6 ng/ml, respectively, p=0.6).  None of the potential confounders were found to be 
significantly associated with 2:16α-OHE levels, so only the unadjusted model results are 
shown (same as in Table 4.8).   
Differences of Estrogen Metabolite Levels by Baseline Dietary Brassica Intake 
 For Aim 2, Table 4.9 depicts unadjusted mean 2-OHE, 16α-OHE, and 2:16α-OHE 
at post intervention by treatment group stratified by baseline dietary Brassica intake; 
whereas, Table 4.10 displays adjusted mean 2-OHE, 16α-OHE, and 2:16α-OHE at post 
intervention by treatment group stratified by baseline dietary Brassica intake.  By using 
the median split of overall Brassica vegetable consumption at baseline, women were 
either categorized as High (≥0.5 srv/d) or Low (<0.5 srv/d) consumers of Brassica 
vegetables. When comparing the intervention to the controls, there was no statistically 
significant difference observed in 2-OHE levels, among high Brassica vegetable 













   
Intervention 10.6 (7.4, 14.9) - 
Control 8.7 (6.0, 12.2) 0.4 
16α-OHE, ng/ml 
3 
   
Intervention 9.6 (7.4, 12.4) - 
Control 8.6 (6.7, 11.0) 0.6 
2:16α-OHE ng/ml    
Intervention 1.3 (1.1, 1.6) - 
Control 1.3 (1.1, 1.6) 0.7 
1
Estrogen metabolite levels (ng/ml) were standardized by dividing by creatinine level (mg/ml). 
2
Logged values used for analysis 
3
LS means for 2-OHE adjusted for marital status, breast cancer survivor status, age, and percent fat mass.  
LS means for 16α-OHE adjusted for percent fat mass. 
4




consumers (9.2 ng/ml vs. 8.4 ng/ml, respectively, p=0.8) or among low Brassica 
vegetable consumers (11.2 ng/ml vs. 8.8 ng/ml, respectively, p=0.4) when adjusted for 
marital status, breast cancer survivorship status, age and baseline percent fat mass.  
Similarly, there was no statistically significant difference in 2:16α-OHE levels between 
intervention and controls, among high Brassica vegetable consumers (1.7 ng/ml vs.1.4 
ng/ml, respectively, p=0.3) or among low Brassica vegetable consumers (1.2 ng/ml 
vs.1.2 ng/ml, respectively, p=0.9).  
Table 4.9: Mean Follow-up of 2-OHE, 16α-OHE and 2:16α-OHE by Treatment Group
1,2
  












2-OHE, ng/ml    
Intervention 14.6 (8.1, 26.0) - 
Control 11.0 (6.5, 18.7) 0.5 
16α-OHE, ng/ml    
Intervention 8.6 (5.5, 13.3) - 
Control 8.1 (5.5, 12.1) 0.9 
2:16α-OHE ng/ml    
Intervention 1.7 (1.2, 2.4) - 
Control 1.4 (1.0, 1.8) 0.3 
Low Brassica Vegetable Consumers
5
 (n=37) 
2-OHE, ng/ml    
Intervention 11.9 (7.5, 18.5) - 
Control 12.7 (7.4, 22.0) 0.9 
16α-OHE, ng/ml    
Intervention 9.8 (7.0, 13.9) - 
Control 10.2 (6.8, 15.3) 0.9 
2:16α-OHE ng/ml    
Intervention 1.2 (0.9, 1.6) - 
Control 1.2 (0.9, 1.7) 0.9 
1
Estrogen metabolite levels (ng/ml) were standardized by dividing by creatinine level (mg/ml). 
2
Logged values used for analysis 
3
p-value represents the difference between intervention groups. 
4
 Baseline dietary Brassica intake and the interaction between treatment group and baseline dietary 
Brassica intake was found to be non-significant in all the estrogen metabolite models. 
5
Median split used to determine whether baseline Brassica consumption was High (≥ 0.5 srv/d) or 
Low (< 0.5 srv/d) 
6




Differences of Estrogen Metabolite Levels by Race 
Table 4.11 displays unadjusted mean 2-OHE, 16α-OHE, and 2:16α-OHE at post 
intervention by treatment group stratified by race; whereas, Table 4.12 shows adjusted 
mean 2-OHE, 16α-OHE, and 2:16α-OHE at post intervention by treatment group 
stratified by race.  When comparing the intervention to the control group, there was no 
statistically significant difference observed in 2-OHE levels, among AA (8.7 ng/ml vs. 
Table 4.10: Adjusted Mean Follow-up of 2-OHE, 16α-OHE and 2:16α-OHE by Treatment 
Group
1,2














   
Intervention 9.2 (5.1, 16.6) - 
Control 8.4 (5.2, 13.6) 0.8 
16α-OHE, ng/ml 
3 
   
Intervention 8.5 (5.6, 12.9) - 
Control 8.0 (5.5, 11.6) 0.8 
2:16α-OHE ng/ml    
Intervention 1.7 (1.2, 2.4) - 
Control 1.4 (1.0, 1.8) 0.3 





   
Intervention 11.2 (7.5, 18.5) - 
Control 8.8 (5.3, 14.6) 0.4 
16α-OHE, ng/ml 
3 
   
Intervention 10.3 (7.4, 14.3) - 
Control 9.5 (6.3, 14.2) 0.7 
2:16α-OHE ng/ml    
Intervention 1.2 (0.9, 1.6) - 
Control 1.2 (0.9, 1.7) 0.9 
1
Estrogen metabolite levels (ng/ml) were standardized by dividing by creatinine level (mg/ml). 
2
Logged values used for analysis 
3
LS means for 2-OHE adjusted for marital status, breast cancer survivor status, age and percent fat 
mass.  LS means for 16α-OHE adjusted for by percent fat mass. 
4
p-value represents the difference between intervention groups. 
5
Median split used to determine whether Brassica consumptions was High (≥ 0.5 srv/d) or Low (< 0.5 
srv/d) 
6
One serving of Brassica is equivalent to 0.5 cups of raw or cooked vegetables 
7
 The interaction between treatment group and baseline dietary Brassica intake was found to be non-




7.0 ng/ml, respectively) and EA women (11.3 ng/ml vs. 9.5 ng/ml, respectively) when 
adjusted for marital status, breast cancer survivorship status, age and baseline percent fat 
mass.  Also, there was no statistically significant difference in 2:16α-OHE levels between 
intervention and controls, among AA (1.4 ng/ml vs.1.0 ng/ml, respectively) and EA 


















African American Women (n=19) 
2-OHE, ng/ml    
Intervention 8.7 (4.7, 16.0) - 
Control 6.5 (3.2, 13.2) 0.5 
16α-OHE, ng/ml    
Intervention 6.4 (4.0, 10.0) - 
Control 6.5 (3.8, 11.2) 0.9 
2:16α-OHE ng/ml    
Intervention 1.4 (1.0, 2.0) - 
Control 1.0 (0.7, 1.5) 0.3 
European American Women (n=47) 
2-OHE, ng/ml    
Intervention 15.3 (10.1, 23.1) - 
Control 14.6 (9.6, 22.2) 0.9 
16α-OHE, ng/ml    
Intervention 11.1 (8.2, 15.2) - 
Control 10.2 (7.4, 14.0) 0.7 
2:16α-OHE ng/ml    
Intervention 1.4 (1.1, 1.8) - 
Control 1.4 (1.1, 1.8) 0.8 
1
Estrogen metabolite levels (ng/ml) were standardized by dividing by creatinine level (mg/ml). 
2
Logged values used for analysis 
3
p-value represents the change between intervention groups. 
4
The interaction between treatment group and race was found to be non-significant in all the 
estrogen metabolite models 
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Table 4.13 displays unadjusted mean 2-OHE, 16α-OHE, and 2:16α-OHE at post 
intervention by race and Table 4.14 displays adjusted estrogen metabolite levels at post 
intervention by race. In the crude analysis (Table 4.13), AA women had significantly 
lower 2-OHE (AA: 7.7 ng/ml; EA: 14.9 ng/ml; p=0.02) and 16α-OHE levels (AA: 6.4 
ng/ml; EA: 10.7 ng/ml; p=0.02) at post intervention.  However, when 2-OHE levels were 
adjusted for marital status, breast cancer survivorship status, age, and baseline percent fat 
mass, the difference among AA and EA women was found to be not statistically 
significant (7.9ng/ml vs. 10.4 ng/ml, respectively, p=0.3) at post intervention. Likewise, 
there was statistically no significant difference in 2:16α-OHE levels among AA and EA 
Table 4.12: Adjusted Mean Follow-up of 2-OHE, 16α-OHE and 2:16α-OHE by 
Treatment Group
1,2









African American Women (n=19) 
2-OHE, ng/ml 
3 
   
Intervention 8.7 (4.7, 16.3) - 
Control 7.0 (3.6, 13.9) 0.6 
16α-OHE, ng/ml 
3 
   
Intervention 7.1 (4.5, 11.2) - 
Control 7.3 (4.3, 12.6) 0.9 
2:16α-OHE ng/ml    
Intervention 1.4 (1.0, 2.0) - 
Control 1.0 (0.7, 1.5) 0.3 
European American Women (n=47) 
2-OHE, ng/ml 
3 
   
Intervention 11.3 (7.5, 16.9) - 
Control 9.5 (6.2, 14.4) 0.5 
16α-OHE, ng/ml 
3 
   
Intervention 11.0 (8.1, 14.9) - 
Control 9.2 (6.7, 12.8) 0.4 
2:16α-OHE ng/ml    
Intervention 1.4 (1.1, 1.8) - 
Control 1.4 (1.1, 1.8) 0.8 
1
Estrogen metabolite levels (ng/ml) were standardized by dividing by creatinine level (mg/ml). 
2
Logged values used for analysis 
3
LS means for 2-OHE adjusted for by marital status, breast cancer survivor, age and percent fat 
mass.  LS means for 16α-OHE adjusted for by percent fat mass. 
4
p-value represents the difference between intervention groups. 
6
The interaction between treatment group and race was found to be non-significant in all the 




women at post intervention (1.2 ng/ml vs. 1.4 ng/ml, respectively, p=0.3).  At post 
intervention, 16α-OHE levels were not significantly different among AA and EA women 
after adjusting for baseline percent fat mass (7.2 ng/ml vs. 10.1  ng/ml, p=0.1).  
 
Differences of Estrogen Metabolites by Breast Cancer Survivorship Status 
Table 4.15 displays unadjusted mean 2-OHE, 16α-OHE, and 2:16α-OHE at post 
intervention by treatment group stratified by breast cancer survivorship status; whereas, 
Table 4.16 shows adjusted mean 2-OHE, 16α-OHE, and 2:16α-OHE at post intervention 









2-OHE, ng/ml    
European American 14.9 (11.1, 19.9) - 
African American 7.7 (4.9, 12.2) 0.02 
16α-OHE, ng/ml    
European American 10.7 (8.5, 13.5) - 
African American 6.4 (4.5, 9.0) 0.02 
2:16α-OHE ng/ml    
European American 1.4 (1.2, 1.6) - 
African American 1.2 (0.9, 1.6) 0.3 
1
Estrogen metabolite levels (ng/ml) were standardized by dividing by creatinine level (mg/ml). 
2
Logged values used for analysis 
3
p-value represents the difference between race. 












   
European American 10.4 (7.6, 14.2) - 
African American 7.9 (4.8, 12.7) 0.3 
16α-OHE, ng/ml 
3 
   
European American 10.1 (8.2, 12.6) - 
African American 7.2 (5.0, 10.2) 0.1 
2:16α-OHE ng/ml    
European American 1.4 (1.2, 1.6) - 
African American 1.2 (0.9, 1.6) 0.3 
1
Estrogen metabolite levels (ng/ml) were standardized by dividing by creatinine level (mg/ml). 
2
Logged values used for analysis 
3
LS means adjusted for marital status, breast cancer survivor status, age and baseline percent fat mass 
for model of 2-OHE by race.  LS means adjusted for baseline percent fat mass for model of 16α-OHE 
by race. 
4




by treatment group stratified by breast cancer survivorship status.  When comparing the 
intervention to the controls at post intervention, there was no statistically significant 
difference detected in 2-OHE levels, among breast cancer survivors (15.9 ng/ml vs. 11.4 
ng/ml, respectively, p=0.2) and disease-free women (6.5 ng/ml vs. 7.5 ng/ml, 
respectively, p=0.7) when adjusted for marital status, breast cancer survivorship status, 
age and baseline percent fat mass.  Also, there was no statistically significant difference 
in 2:16α-OHE levels between intervention and controls, among breast cancer survivors 
(1.6 ng/ml vs.1.3 ng/ml, respectively, p=0.3) and disease-free women (1.0 ng/ml vs.1.2 
ng/ml, respectively, p=0.4) at post intervention. 
Table 4.15: Mean Follow-up of 2-OHE, 16α-OHE and 2:16α-OHE by Treatment Group
1,2
 









Breast Cancer Survivor (n=18) 
2-OHE, ng/ml    
Intervention 16.0 (10.7, 24.0) - 
Control 13.4 (8.8, 20.5) 0.6 
16α-OHE, ng/ml    
Intervention 10.3 (7.5, 14.0) - 
Control 10.1 (7.3, 14.0) 0.9 
2:16α-OHE ng/ml    
Intervention 1.6 (1.2, 2.0) - 
Control 1.3 (1.0, 1.7) 0.3 
Disease-Free (n=48) 
2-OHE, ng/ml    
Intervention 7.3 (3.9, 13.9) - 
Control 8.1  (4.0, 16.6) 0.8 
16α-OHE, ng/ml    
Intervention 7.4 (4.5, 12.2) - 
Control 6.6 (3.8, 11.5) 0.8 
2:16α-OHE ng/ml    
Intervention 1.0 (0.7, 1.4) - 
Control 1.2 (0.8, 1.9) 0.4 
1
Estrogen metabolite levels (ng/ml) were standardized by dividing by creatinine level (mg/ml). 
2
Logged values used for analysis 
3
p-value represents the difference between intervention groups. 
4
The interaction between treatment group and breast cancer survivorship was found to be non-




Table 4.16: Adjusted Mean Follow-up of 2-OHE, 16α-OHE and 2:16α-OHE by Treatment 
Group
1,2









Breast Cancer Survivor (n=18) 
2-OHE, ng/ml 
3 
   
Intervention 15.9 (11.0, 23.1) - 
Control 11.4 (7.8, 16.8) 0.2 
16α-OHE, ng/ml 
3 
   
Intervention 10.3 (7.6, 14.0) - 
Control 9.2 (6.7, 12.8) 0.6 
2:16α-OHE ng/ml    
Intervention 1.6 (1.2, 2.0) - 




   
Intervention 6.5 (3.6, 11.7) - 
Control 7.5  (4.0, 14.4) 0.7 
16α-OHE, ng/ml 
3 
   
Intervention 7.9 (4.9, 12.8) - 
Control 7.2 (4.2, 12.4) 0.8 
2:16α-OHE ng/ml    
Intervention 1.0 (0.7, 1.4) - 
Control 1.2 (0.8, 1.9) 0.4 
1
Estrogen metabolite levels (ng/ml) were standardized by dividing by creatinine level (mg/ml). 
2
Logged values used for analysis 
3
LS means for 2-OHE adjusted for by age, marital status, breast cancer survivorship and percent fat 
mass.  LS means for 16α-OHE adjusted for by percent fat mass. 
4
p-value represents the difference between intervention groups. 
5
The interaction between treatment group and breast cancer survivorship was found to be non-
significant in all the estrogen metabolite models.  
 
Table 4.17 shows unadjusted mean 2-OHE, 16α-OHE, and 2:16α-OHE at post 
intervention by breast cancer survivorship status and Table 4.18 displays adjusted 
estrogen metabolite levels at post intervention by breast cancer survivorship status. In the 
crude analysis (Table 4.17), disease-free women had statistically significantly lower 2-
OHE levels at post intervention (breast cancer survivor: 14.7 ng/ml; disease-free: 7.7 
ng/ml; p=0.02).  Correspondingly, differences in 2-OHE levels remained statistically 
significant among breast cancer survivors and disease-free women after adjusting for 
marital status, age, and baseline percent fat mass (13.5 ng/ml vs. 6.8 ng/ml, respectively, 
p=0.01).  At post intervention, 2:16α-OHE levels were observed to be nearly significant 
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among breast cancer survivors and disease-free women (1.4 ng/ml vs.1.1 ng/ml, 
respectively, p=0.09).  The differences in 16α-OHE levels were observed to be higher in 
breast cancer survivors than disease-free women, though this was non-significant (9.8 
ng/ml vs. 7.6 ng/ml, respectively).  










2-OHE, ng/ml    
Breast Cancer Survivor 14.7 (11.0, 20.0) - 
Disease-Free 7.7 (5.0, 12.2) 0.02 
16α-OHE, ng/ml    
Breast Cancer Survivor 10.2 (8.2, 12.2) - 
Disease-Free 7.0 (5.0, 10.0) 0.09 
2:16α-OHE ng/ml    
Breast Cancer Survivor 1.4 (1.2, 1.7) - 
Disease-Free 1.1 (0.8, 1.4) 0.09 
1
Estrogen metabolite levels (ng/ml) were standardized by dividing by creatinine level (mg/ml). 
2
Logged values used for analysis 
3
p-value represents the difference between breast cancer survivorship status (yes/no). 
 












   
Breast Cancer Survivor 13.5 (10.4, 17.6) - 
Disease-Free 6.8 (4.3, 10.7) 0.01 
16α-OHE, ng/ml 
3 
   
Breast Cancer Survivor 9.8 (7.9, 12.2) - 
Disease-Free 7.6 (5.3, 10.8) 0.2 
2:16α-OHE ng/ml    
Breast Cancer Survivor 1.4 (1.2, 1.7) - 
Disease-Free 1.1 (0.8, 1.4) 0.09 
1
Estrogen metabolite levels (ng/ml) were standardized by dividing by creatinine level (mg/ml). 
2
Logged values used for analysis 
3
LS means adjusted for marital status, age and baseline percent fat mass for model of 2-OHE by breast 
cancer survivorship status.  LS means adjusted for baseline percent fat mass for model of 16α-OHE by 
breast cancer survivorship status. 
4







 Over the last few years, diet has emerged as an important environmental risk 
factor associated with the risk of a number of cancers, including breast cancer.  The link 
between vegetables in general and the risk of breast cancer has been well-established 
through numerous studies over the last decade (Willet 2001; La Vecchia et al. 2001; 
Riboli et al. 2003; Gandini et al. 2001; Cottet et al. 2009); however, the link between 
Brassica vegetable consumption and the risk of breast cancer have continued to yield 
inconsistent results, making this present study critical in helping to understand the 
biological mechanism of this link.  In the present study, compared to baseline levels, 
Brassica vegetable intake significantly increased in the intervention group by 6-fold 
when compared to control group during the intervention; whereas, post intervention, 
Brassica intake only increased in the intervention about 3.5-fold when compared to the 
control group.  Also, during the intervention, total dietary fiber mean intake significantly 
increased in both treatment groups; and total fruit and vegetable mean intake, total 
vegetable mean intake and total soluble fiber mean intake significantly increased in the 
intervention group only.  Post intervention showed statistically significant increases in 
total soluble fiber mean intake and total mean vegetable intake only in the intervention 
group; and total fruit mean intake increased in the control group only.  Another 
observation noted among the intervention group only, was that the mean servings of 
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vegetables, fruit and vegetables, and Brassica vegetables during the intervention was 
higher than servings consumed post intervention.   
 Estrogen is a well-established risk factor for breast cancer.  2-OHE and 16α-OHE 
are two estrogen metabolites of most interest which together are often reported as 2:16α-
OHE ratio.  A higher incidence of disease tends to be associated with high levels of 16α-
OHE and low levels of 2-OHE in the body according to some studies (Matthews et al. 
2004; Musey et al. 1987), but not all (Obi et al. 2011; Lissowska et al. 2008; Ursin et al. 
1999; Cauley et al. 2003; Wellejus et al. 2005).  Estrogen is metabolized along two 
competing pathways, 2-OHE and 16α-OHE.  A few studies have demonstrated that 
Brassica vegetables play a significant role in the overall mechanism in modulating the 
activity of cellular enzymes that are responsible for the production of these estrogen 
metabolites, indole-3-carbionol (I3C) in particular (Maizes 2005; Lord et al. 2002; 
Nguyen et al. 2010; Laidlaw et al.2010; Dalessandri et al. 2004).   
In the present study, both crude and final adjusted analyses showed no significant 
differences in 2-OHE, 16α-OHE and 2:16α-OHE as a result of an intense three-week 
Brassica vegetable dietary intervention.  Even when adjusted for baseline estrogen 
metabolite levels, the intervention group did have higher levels of 2-OHE levels than 
those in the control when adjusted for marital status, breast cancer survivorship status, 
age and percent fat mass; however, this was statistically non-significant.  It seemed 
plausible that no significant change was observed post intervention because women may 
have already been consuming high amounts of Brassica vegetables at baseline; therefore, 
to assess whether or not diet before the Brassica intervention began had an overall impact 
on the result of the intervention, a by statement was used to stratify by baseline dietary 
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Brassica intake.  Overall Brassica vegetable consumption at baseline was categorized 
using a median split, women were categorized as High (≥ 0.5 srv/d) or Low (< 0.5 srv/d) 
consumers.  Women who were categorized as low Brassica vegetable consumers at 
baseline did show higher increases in their 2-OHE levels after adjusting for marital status, 
breast cancer survivorship status, age, and baseline percent fat mass; but, these levels 
were statistically non-significant.  Though the difference in the 2-OHE levels was 
statistically non-significant, the results of the Brassica intervention do show that 2-OHE 
levels can possibly be modified through diet.  
   Unlike this study, there have been a few epidemiological studies that have 
significantly shown an increase in 2-OHE levels after consumption of I3C (Nguyen et al. 
2010; Laidlaw et al. 2010; Marconett et al. 2010).  In a study by Laidlaw et al. (2010), 
pre and postmenopausal women were randomized to receive either the placebo 
(supplement containing microcrystalline cellulose) or treatment (supplement containing 
200 mg I3C and 10 mg HMR ligans) for a period of 28 days.  Among postmenopausal 
women receiving a supplement of I3C and HMR ligans, a significant increase in the 2-
OHE levels was observed but no significant change in the 2:16α-OHE levels (Laidlaw et 
al. 2010).  It may be that supplements containing high levels of I3C may have a 
significantly greater effect on 2-OHE rather than 16α-OHE levels.  Further research 
needs to be conducted at the genetic level on the biological mechanism behind the 
CYP1A1 enzyme that catalyzes the conversion of estrone to 2-OHE, which has been 
shown to be impacted by the phytochemical I3C found in Brassica vegetables. 
 It has been heavily documented in numerous studies that AA women are less 
likely to be diagnosed with breast cancer than their EA counterparts; however, AA 
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women are more likely to die of breast cancer than EA women when they are diagnosed 
(DeSantis et al. 2013; SEER, Stat Fact Sheets: Breast Cancer 2006-2010; Adams et al. 
2006; Menashe et al. 2009). It is vital that the health disparity that exists between EA and 
AA women, in terms of breast cancer mortality, be addressed; furthermore, it has also 
been observed that AA women tend to have lower 2:16α-OHE levels than EA women 
(Soweres et al. 2006; Lord et al. 2002; Matthews et al. 2004; Musey et al. 1987).  
Therefore, in this present study, the effects of Brassica vegetable consumption and breast 
cancer survivors on the 2:16α-OHE among AA women was examined.   
In the present study, levels of estrogen metabolites post intervention were 
compared between AA and EA women, regardless of whether or not they were in the 
intervention. Crude analysis showed that AA women compared to EA women had 
significantly lower levels of both 2-OHE and 16α-OHE levels; though no significant 
difference was seen in 2:16α-OHE levels among the two races.  Conversely, after 
adjustment for marital status, breast cancer survivorship status, age, and baseline percent 
fat mass, 2-OHE levels remained lower in AA women compared to EA women but this 
difference was statistically non-significant.  16α-OHE levels, after adjusting for baseline 
percent fat mass at post intervention, showed a slight suggestion of lower levels among 
AA compared to EA women but this difference was also statistically non-significant.  
The association of race was further assessed on its impact of estrogen metabolite levels 
on the actual three-week intervention.  In both crude and adjusted analyses, when 
comparing the intervention and the control groups post intervention, there was no 
statistically significant difference observed in 2-OHE, 16α-OHE and 2:16α-OHE levels 
among AA and EA women.  In contrast to this study‟s finding, a case-control study 
57 
 
among EA and AA pre and postmenopausal women by Coker et al. (1997) found that AA 
women had significantly lower 2-OHE (adjusted for creatinine) levels than EA; 
additionally, though not significant, AA women also had lower mean levels of 2:16α-
OHE ratios than EA.  
In a similar manner, levels of estrogen metabolites post intervention were 
compared between breast cancer survivors and disease-free women, regardless of 
whether or not they were in the intervention.  Crude analysis showed that breast cancer 
survivors compared to disease-free women had significantly higher levels of 2-OHE.  
Breast cancer survivors were also observed to have higher levels of 16α-OHE and 2:16α-
OHE levels that showed a slight suggestion of an association but it was statistically non-
significant.  Similarly, 2-OHE levels remained statistically significantly higher among 
breast cancer survivors compared to disease- free women after adjusting for marital 
status, age, and baseline percent fat mass.  In the final adjusted model for 16α-OHE, the 
difference between breast cancer survivors compared to disease-free women was found to 
be statistically non-significant.  The association of breast cancer survivor status was 
further assessed on its impact of estrogen metabolite levels on the actual three-week 
intervention.  In both crude and adjusted analyses, when comparing the intervention and 
the control groups post intervention, there was no statistically significant difference 
observed in 2-OHE, 16α-OHE and 2:16α-OHE levels among breast cancer survivors and 
disease-free women.  Ours is the first study to examine whether effects of Brassica 
vegetables on estrogen metabolites differ by breast cancer survivor status. Other larger 
studies are needed to confirm these findings of no difference in effect between breast 
cancer survivor and disease-free postmenopausal women.  
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Strengths and Limitations 
 The present study has several strengths and some limitations.  The small sample 
size used in this study is a major limitation which ultimately leads to low power and, 
concomitantly, wide confidence intervals; therefore, leading to significant associations 
possibly being masked.  Another limitation in terms of the sample population is that only 
about one-fourth of the study participants were AA women, which reduced power even 
further in race-stratified analyses.    Also, late age at first birth and dose and type of 
hormone replacement therapy were not available in the dataset so they could not be 
examined as possible confounders during analyses.  It is well-documented that these 
variables are known risk factors for breast cancer.   
Study duration and intensity of our intervention are also possible limitations to 
consider.  Our three-week intervention may not have been long enough to observe a 
significant shift in 2:16α-OHE ratios; nonetheless, this seems to vary by study.  A three-
month study by Morrison et al. (2009) observed a significant overall mean improvement 
of 168% in 2:16α-OHE among 13 women with addition of 3.6 grams of powdered 
organic Brussels sprouts and organic kale to their diet (p=0.01); however, this was in 
premenopausal women.  Fowke et al (2000) demonstrated similar results in 34 
postmenopausal women but the intervention was over a 4-week period to increase 
Brassica consumption to at least 70mg/day.  Brassica vegetable consumption increased 
about 20-fold from baseline to after the intervention (respectively, 9g/d to 193g/d) in 
which 2:16α-OHE ratio statistically significantly increased from 2.27 to 2.38 when 
adjusted for water-soluble fiber, protein, energy and social approval score (Fowke et al. 
2000).    Our study was similar in duration to Fowke et al. 2000 but Brassica vegetable 
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consumption only increased about 6-fold during our intervention, which is a smaller 
increase than the 20-fold increase Fowke et al. 2000 observed.  Therefore, we cannot 
exclude the possibility that a more intense intervention would have observed a larger 
effect.   
Other common limitations deal with different types of biasness.  Attrition bias is a 
concern among randomized clinical trials.  In this present study, 96 women were initially 
randomized into either the intervention or control group (51 intervention and 45 
controls); however, by the time the study was completed, there were only 64 women (34 
intervention and 30 controls) with complete data.  Also, information bias is possible in 
terms of reporting dietary intake through the 24-hour recalls used in this study.  One 
possible reason is due to the detail about the intake relying heavily upon the participant‟s 
memory.  Lastly, there may be a reporting effect related to social desirability where 
participants may over-report the intake of healthy foods and under-report alcohol, high 
calorie and high fat foods in hopes of pleasing the interviewer.  However, though 24-hour 
recalls do have these limitations, this study tried to control for some of them by having 
trained dietitians administering the recalls, and administering multiple recalls on non-
consecutive days in order to obtain a representative sample of the participant‟s actual 
dietary intake. 
One of the major strengths of this study, as well as other randomized clinical 
trials, is minimized allocation bias due to the randomization of participants into study 
groups.  This allows the investigator to isolate and quantify the effect of the actual 
intervention that is being conducted, and decreases the chance of confounding by other 
factors.  Furthermore, this allowed for the manipulation of our exposure, increase 
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Brassica vegetable consumption, by women being randomized to the intervention or 
control group in which dietary habits were supposed to remain unchanged.  Another 
strength is that a number of potential confounders were assessed in order to determine 
which ones would be controlled for in the final estrogen metabolite models.  Covariates 
included in the models included marital status, breast cancer survivorship status, age, and 
baseline percent fat mass in the 2-OHE models and baseline percent fat mass in the 16α-
OHE models. 
To our knowledge, this is one of few studies to examine the effects of Brassica 
vegetables on the 2:16α-OHE ratio among postmenopausal AA women and breast cancer 
survivors.  Although the results of this present study are not generalizable to the 
population as a whole due to demographic differences, the information observed can be 
used by other studies, those involved in preventive cancer programs, and by clinicians. 
 In summary, these finding suggests that Brassica vegetables do not play a role in 
the modification of 2-OHE and 2:16α-OHE metabolite levels among postmenopausal 
women in a short intervention.  These findings highlight the need for future research to 
further understand the biological mechanism between estrogen metabolites and Brassica 
vegetable consumption because it could lead to a possible preventive measure to not only 
reduce the risk of breast cancer and other comorbidities among women in general but to 
also reduce the health disparity that exist between AA and EA women. 
Future Research 
 Future research is needed to examine whether 2-OHE, 16α-OHE and 2:16α-OHE 
metabolite levels can be modified through increased Brassica vegetable consumption in 
hopes that they could play a vital role in reducing the risk of breast cancer among all 
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women.  To improve the current study, a larger randomized clinical trial to determine if 
2-OHE, 16α-OHE and 2:16α-OHE levels can be modified by increased Brassica 
vegetable consumption is one recommendation.  Increasing the sample size would help to 
increase power to observe significant associations. Furthermore, it is vital to close the 
health disparity gap that exists between AA and EA women, so increasing the percentage 
of AA women in a study like this could also improve the study design.  Determining the 
amount of Brassica vegetables and specific types of Brassica vegetables needed to 
observe a change in estrogen metabolite levels would also be considered beneficial.  
Other possible confounders that were not specifically analyzed included age at first birth 
and medications, in particular hormone replacement therapies and supplements.  Women 
were asked to maintain a stable, fixed dose of any medications (including hormone 
replacement therapy) and supplements throughout the study period but having data to 
adjust during analyses could be useful.  Lastly, further research of these estrogen 
metabolite levels in different racial groups may be influenced not only by lifestyle and 
environmental factors but by genetic factors as well.  It is highly possible that AA and 
EA women, as well as other races, have variations in the CYP1A1 and CYP1B1 genotypes 
that could maybe explain why the overall levels of 2-OHE and 16α-OHE metabolite 






Research on the effects of Brassica vegetable consumption on the 2:16α-OHE 
metabolite ratio in randomized clinical settings is still sparse; in addition, the effect of 
Brassica vegetables on the estrogen metabolite ratio among AA women and breast cancer 
survivors has not thoroughly been examined.  This study provided an opportunity to 
further explore the effects of Brassica vegetable intake on the 2:16α-OHE metabolite 
ratio among postmenopausal EA and AA women.  Brassica vegetables have been linked 
to lowering the risk of other types of cancer, in particular lung and colorectal cancer, in 
some epidemiological studies; therefore, the research on this topic is critical (Kim et al. 
2009).  The 2:16α-OHE metabolite ratio can be potentially modified through lifestyle 
factors like diet.  It is vital to further understand the biological mechanism of the link 
between Brassica vegetables and breast cancer risk.  Subsequently, this may help to 
inform future interventions designed to reduce the risk of breast cancer; moreover, also 
help in closing the health disparity that exists between AA and EA women. 
Although several studies have shown that increasing the number of servings of 
Brassica vegetables can decrease the 2:16α-OHE ratio, this study found no significant 
differences in either the 2-OHE or 2:16α-OHE metabolite levels after an intense three-
week Brassica intervention.  Furthermore, this lack of association was not modified by 
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any of the potential anthropometric, demographic, or dietary intake characteristics.  When 
controlled for baseline estrogen metabolite levels, the intervention group was found to 
have higher levels of 2-OHE levels than control group, adjusted for marital status, breast 
cancer survivorship status, age and baseline percent fat mass; however, this difference 
was statistically non-significant.  It was observed that AA women compared to EA 
women, overall had lower levels of 2-OHE and 16α-OHE throughout the study but there 
was no difference in the ratio of the estrogen metabolites between ethnic groups.  
Similarly, differences by breast cancer status were observed whereby 2-OHE levels 
remained significantly higher among breast cancer survivors compared to disease free 
women after adjusting for marital status, age, and baseline percent fat mass.  
Future research is needed to determine whether a larger increase in Brassica 
vegetables could affect estrogen metabolites and to examine whether genes may modify 
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